JAK2 Expression in Androgenetic Alopecia Before and After Topical Minoxidil
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Topical Minoxidil 5% Solution, Scalp Punch Biopsy, Tissue JAK2 Protein Measurement by ELISA.
- Who it may be relevant to
- Registry conditions: Androgenetic Alopecia, Androgenic Alopecia. Basic parameters: 18 years — 50 years · Male.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Assessment of Janus Kinase 2 Expression in Patients With Androgenic Alopecia and Its Modulation by Topical Minoxidil Therapy.
Overview
Androgenetic alopecia is a common form of progressive hair loss. This prospective single-arm pre-post interventional study aims to assess tissue Janus Kinase 2 (JAK2) expression in patients with androgenetic alopecia by comparing balding and non-balding scalp at baseline, and to evaluate changes in JAK2 expression in balding scalp after 3 months of topical minoxidil 5% therapy. Clinical response will be assessed using standardized trichoscopic parameters.
Detailed description
This study will recruit 25 adult patients aged 18 to 50 years with mild to moderate androgenetic alopecia attending the Dermatology outpatient clinic, Cairo University Hospital. At baseline, participants will undergo clinical evaluation, standardized photography, and trichoscopic assessment. Three 2 mm scalp punch biopsies will be obtained over the course of the study: one from the balding scalp area and one from the non-balding scalp area at baseline, and one from the balding area after 3 months of therapy. Tissue JAK2 protein levels will be measured by ELISA. Participants will receive topical minoxidil 5% solution for 3 months (1 cc twice daily for men and once daily for women). The primary endpoint is the comparison of tissue JAK2 levels between balding and non-balding scalp at baseline. Secondary analyses will assess change in JAK2 levels after treatment and correlations with clinical improvement by trichoscopy.
Interventions
- Drug Topical Minoxidil 5% Solution
Topical minoxidil 5% solution applied to the affected scalp areas for 12 weeks. Men will apply 1 cc twice daily and women will apply 1 cc once daily. - Procedure Scalp Punch Biopsy
Three 2 mm punch biopsies will be obtained during the study: one from the balding scalp area and one from the non-balding scalp area at baseline, and one from the balding scalp area after 12 weeks of treatment. - Diagnostic test Tissue JAK2 Protein Measurement by ELISA
Tissue samples obtained from scalp punch biopsies will be analyzed for Janus Kinase 2 (JAK2) protein levels using ELISA at baseline and after 12 weeks of treatment.
Primary outcome measures
- Baseline Difference in Tissue JAK2 Protein Levels Between Balding and Non-Balding Scalp [Time frame: Baseline]
Secondary outcome measures (3)
- Change in Tissue JAK2 Protein Levels in Balding Scalp After 12 Weeks of Topical Minoxidil [Time frame: Baseline to Week 12]
- Change in Trichoscopic Hair Parameters After 12 Weeks of Treatment [Time frame: Baseline to Week 12]
- Correlation Between Change in Tissue JAK2 Levels and Clinical Response [Time frame: Week 12]
Eligibility criteria
Inclusion criteria
- Male adults aged 18 to 50 years with androgenetic alopecia.
- Mild to moderate disease severity, defined as Hamilton-Norwood scale II to V.
- Patients who are treatment-naive or willing to undergo an adequate washout period for prior hair loss therapies of at least 1 month.
- Willing and able to provide written informed consent.
Exclusion criteria
- Other types of hair loss, including inflammatory or scarring alopecia.
- Inflammatory scalp dermatoses, such as psoriasis or seborrheic dermatitis.
- Use of systemic immunosuppressants, JAK inhibitors, or systemic corticosteroids within the last 12 months.
- History of severe systemic disease, including renal, cardiovascular, or hepatic disease.
- Chemotherapy during the last 5 years.
- Bleeding disorders.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Kasr El Aini Hospital — Cairo
Identifiers
NCT: NCT07563036 · MS-655-2025